T-cell Acute Lymphoblastic Leukemia (T-ALL): Understanding Your Pathology Report

by David Li MD
June 23, 2026

T-cell acute lymphoblastic leukemia (T-ALL) is a type of blood cancer that starts from immature T cells, a type of white blood cell that normally helps control the immune response and fight viruses. These immature, abnormal cells are called lymphoblasts. In T-ALL, the lymphoblasts accumulate in the bone marrow and blood, crowding out normal blood cells. T-ALL is most common in older children, teenagers, and young adults, and it affects males more often than females. It often causes a mass in the center of the chest (a thymus or mediastinal mass), and it can spread to the fluid around the brain and spinal cord.

This article will help you understand the findings in your pathology report for T-cell acute lymphoblastic leukemia, what each term means, and why it matters for your care or the care of your child.

What causes T-cell acute lymphoblastic leukemia?

The exact cause of T-cell acute lymphoblastic leukemia (T-ALL) is usually not known. Most cases arise when genetic changes accumulate by chance in a developing T cell, allowing it to grow out of control as a lymphoblast. A few factors are known to increase the risk:

Random DNA changes — Most cases happen because of genetic changes that occur by chance as cells divide. These are not inherited and cannot be passed to children.
Previous radiation or chemotherapy — Earlier treatment for another cancer can increase the risk.
Inherited predisposition — Rarely, an inherited condition that affects how cells repair DNA or control growth can raise the risk.

For most patients, T-ALL has no clear cause, is not contagious, and cannot be prevented.

What are the symptoms of T-cell acute lymphoblastic leukemia?

The symptoms of T-cell acute lymphoblastic leukemia (T-ALL) result from lymphoblasts filling the bone marrow and may include a mass in the chest.

Common symptoms include:

Shortness of breath or chest pressure — A mass in the center of the chest, or fluid building up around the lungs or heart, can make breathing difficult.
Fatigue and weakness — Caused by a shortage of red blood cells (anemia).
Easy bruising or bleeding — Caused by a shortage of platelets.
Bone or joint pain — Caused by the buildup of lymphoblasts inside the bones.
An enlarged liver or spleen, or swollen lymph nodes.

Blood tests in people with T-ALL often show a very high white blood cell count.

What is the difference between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma?

T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are the same type of cancer but differ mainly in where it is found. When the cancer cells are mainly in the blood and bone marrow, it is called T-ALL. When they are mainly in the lymph nodes, thymus, or other tissues outside the bone marrow, it is called T-LBL. The two conditions are treated in a similar way.

How is the diagnosis made?

The diagnosis of T-cell acute lymphoblastic leukemia (T-ALL) is made by examining the blood and bone marrow. A complete blood count (CBC) is usually the first test and often shows a high white blood cell count along with low red blood cell and platelet counts. To confirm the diagnosis, a sample of the bone marrow is obtained via bone marrow aspiration and biopsy, usually from the back of the hip bone after the area is numbed. A pathologist examines the sample under the microscope and counts the proportion of blasts.

Flow cytometry is the main test used to confirm that the blasts are immature T cells. It measures proteins on and inside cells, and in T-ALL, the lymphoblasts typically express T-cell markers such as CD3 (including CD3, which is specific for T cells), CD7, CD1a, CD4, and CD8, along with immaturity markers such as TdT and CD34. Immunohistochemistry, which also uses antibodies to detect specific proteins, may be used. Chromosome and molecular tests look for the genetic changes described later in this article. Because T-ALL often forms a mass in the chest and can spread to the central nervous system, imaging tests such as CT scans are used to look for a chest mass, and a sample of the fluid around the brain and spinal cord (cerebrospinal fluid) is collected through a lumbar puncture to check for spread.

What does T-cell acute lymphoblastic leukemia look like under the microscope?

Under the microscope, T-cell acute lymphoblastic leukemia (T-ALL) consists of lymphoblasts, immature T cells that have not yet finished developing. Normally, T cells mature in steps, but in T-ALL, they stay stuck in an early, immature state. Each lymphoblast is round, with a large nucleus (the part of the cell that contains the genetic material) that occupies most of the cell, surrounded by only a thin rim of cytoplasm. The bone marrow is usually packed with these cells, which replace the normal blood-forming cells, and they may also be seen in large numbers in the blood.

Genetic changes and molecular testing in T-cell acute lymphoblastic leukemia

T-cell acute lymphoblastic leukemia (T-ALL) is studied for genetic changes in lymphoblasts, which help classify the disease, predict its behavior, and determine eligibility for clinical trials. Pathologists look for these changes using tests such as FISH (fluorescence in situ hybridization), PCR (polymerase chain reaction), and next-generation sequencing (NGS). Common changes include:

Translocations — A translocation happens when a piece of DNA is swapped between two chromosomes. In T-ALL, a translocation often places a growth-driving gene next to the genes that normally control T cells (on chromosomes 14 and 7), switching the growth gene on.
Deletions — A deletion is a missing piece of DNA. A common one in T-ALL involves a gene called CDKN2A on chromosome 9, which normally helps slow cell growth.
NOTCH1 and FBXW7 mutations — Changes in these genes are among the most common in T-ALL. They allow the cancer cells to survive longer and divide more quickly.

Unlike B-cell ALL, T-ALL does not usually carry the BCR::ABL1 fusion (Philadelphia chromosome), so the targeted drugs used for that change do not generally apply. Your report will describe any genetic changes that were found.

Early T-cell precursor ALL (ETP-ALL)

About 1 in 10 cases of T-cell acute lymphoblastic leukemia (T-ALL) is a special type called early T-cell precursor ALL (ETP-ALL). In this type, the lymphoblasts are captured at a very early stage of T-cell development and express an unusual mix of markers, including some normally found on other blood cell types. ETP-ALL was once considered higher risk, but with current treatment, many patients have outcomes similar to other types of T-ALL. Your report may note whether the leukemia is the ETP type.

Measurable residual disease (MRD)

After treatment for T-cell acute lymphoblastic leukemia (T-ALL) begins, very sensitive tests such as flow cytometry, PCR, or NGS are used to look for tiny numbers of leukemia cells that may remain, sometimes as few as one cancer cell among a million normal cells. This is called measurable residual disease, also called minimal residual disease (MRD). The MRD result is one of the strongest predictors of whether the leukemia will return, and it is used to decide whether treatment should be intensified.

What is the prognosis for T-cell acute lymphoblastic leukemia?

Prognosis means the expected outcome of a disease. Unlike most solid tumors, T-cell acute lymphoblastic leukemia (T-ALL) is not assigned a stage based on size or spread because it begins in the bone marrow and blood rather than as a single mass. Instead, the likely outcome is estimated from a combination of factors:

Age — Children and teenagers generally do better than adults.
White blood cell count at diagnosis — A very high count is associated with a higher risk.
Genetic changes — Certain patterns of genetic change are linked with a higher or lower risk.
Spread to the central nervous system — Leukemia cells found in the cerebrospinal fluid require additional treatment directed at the brain and spinal cord.
Response to treatment (MRD) — Reaching an MRD-negative result, meaning no leukemia can be detected by sensitive testing, is one of the most favorable signs.

With current treatment, most children and teenagers with T-ALL do well, with five-year survival of roughly 80 to 90%. Outcomes in adults have historically been lower, around 50%, but they have improved as T-ALL-specific drugs such as nelarabine have been added to treatment. Your prognosis depends on your own combination of these factors, which your care team can explain in the context of your specific report.

What happens after a diagnosis of T-cell acute lymphoblastic leukemia?

Once T-cell acute lymphoblastic leukemia (T-ALL) is confirmed, the care team plans treatment based on the patient’s age, the genetic changes found, and the overall risk. Treatment is usually given over about two to three years, in phases. The findings on the pathology report shape several decisions:

Combination chemotherapy — The backbone of treatment, given in phases (often called induction, consolidation, and maintenance) to bring the leukemia into remission and keep it there.
Treatment aimed at the brain and spinal cord — Because T-ALL has a higher chance of spreading to the central nervous system, chemotherapy is given into the cerebrospinal fluid through a lumbar puncture, and radiation is sometimes used.
Nelarabine — A chemotherapy drug that works specifically against T-cell leukemia and lymphoma. It is increasingly part of treatment, including for diseases that have recurred or not responded.
Stem cell (bone marrow) transplant — An allogeneic transplant, using blood-forming cells from a donor, may be considered for higher-risk or relapsed disease.

The immunotherapies and CAR T-cell treatments that target B-cell markers in B-cell ALL do not apply to T-ALL, because T-ALL cells are a different cell type. For this reason, clinical trials of newer treatments are an important option to discuss, especially for disease that has come back. Throughout treatment, blood counts, repeat bone marrow biopsies, and MRD testing are used to measure how well the leukemia is responding, and the results guide whether more therapy is needed. Care is provided by a team that usually includes a hematologist or oncologist, specialized nurses, and supportive care specialists. Decisions about which of these approaches apply are made by the treatment team together with the patient or family, based on the specific findings in the report.

Questions to ask your doctor

Is my leukemia the T-cell type, and is it the early T-cell precursor (ETP) type?
What did the flow cytometry show about the markers on the leukemia cells?
Were any genetic changes found, such as a translocation, a deletion, or a NOTCH1 or FBXW7 mutation?
Do I have a mass in my chest, and will that affect my treatment?
Has the leukemia spread to the cerebrospinal fluid or central nervous system?
Will I need treatment directed at the brain and spinal cord?
Am I (or is my child) considered standard risk or high risk, and what does that mean?
What treatment phases should I expect, and how long will treatment last?
Will Nelarabine be part of my treatment?
How will measurable residual disease (MRD) be tested, and how will the results affect my treatment?
Might I need a stem cell (bone marrow) transplant?
Are there clinical trials that I should consider?